Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Sign up to receive an email alert when a clinical trial location in your area begins accepting patients.
When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.